Givlaari Shows Safety, Efficacy Over Long-term for Acute Hepatic Porphyria

Givlaari Shows Safety, Efficacy Over Long-term for Acute Hepatic Porphyria

309750

Givlaari Shows Safety, Efficacy Over Long-term for Acute Hepatic Porphyria

Long-term treatment with Givlaari (givosiran) is safe and provides sustained clinical benefits to people with acute hepatic porphyria (AHP), according to an interim, two-year analysis of a Phase 3 trial’s ongoing extension, presented at a science conference. These data are in line with previous trial findings, showing that the therapy can improve the quality of life of patients with AHP, Alnylam Pharmaceuticals, which developed and markets Givlaari, stated in a press release. AHP is caused by…

You must be logged in to read/download the full post.